TP53 and myelodysplastic syndrome: The wide range of therapeutic strategies available for TP53-mutated MDS cases was recently excellently described [7]; herein we aim just to summarize the main standard and emerging approaches in order to show how the study of TP53 alterations in MDS patients can influence treatment decision-making and predict the response rate.